Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Protagonist Therapeutics (PTGX) Operating Expenses (2017 - 2025)

Protagonist Therapeutics' Operating Expenses history spans 9 years, with the latest figure at $57.8 million for Q4 2025.

  • For Q4 2025, Operating Expenses rose 31.77% year-over-year to $57.8 million; the TTM value through Dec 2025 reached $204.1 million, up 12.42%, while the annual FY2025 figure was $204.1 million, 12.42% up from the prior year.
  • Operating Expenses for Q4 2025 was $57.8 million at Protagonist Therapeutics, up from $51.1 million in the prior quarter.
  • Across five years, Operating Expenses topped out at $57.8 million in Q4 2025 and bottomed at $30.2 million in Q1 2021.
  • The 5-year median for Operating Expenses is $43.4 million (2024), against an average of $42.5 million.
  • The largest annual shift saw Operating Expenses soared 111.68% in 2021 before it dropped 26.94% in 2022.
  • A 5-year view of Operating Expenses shows it stood at $45.6 million in 2021, then fell by 19.98% to $36.5 million in 2022, then rose by 1.19% to $37.0 million in 2023, then rose by 18.69% to $43.9 million in 2024, then skyrocketed by 31.77% to $57.8 million in 2025.
  • Per Business Quant, the three most recent readings for PTGX's Operating Expenses are $57.8 million (Q4 2025), $51.1 million (Q3 2025), and $47.6 million (Q2 2025).